Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $9.75.

Several research firms have issued reports on ACRS. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, December 29th.

Aclaris Therapeutics Stock Down 4.3%

Shares of NASDAQ:ACRS opened at $2.88 on Monday. The firm has a market cap of $312.05 million, a P/E ratio of -2.09 and a beta of 0.41. Aclaris Therapeutics has a 12 month low of $1.05 and a 12 month high of $3.47. The company’s 50-day moving average price is $2.76 and its two-hundred day moving average price is $2.12.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $3.30 million for the quarter, compared to analyst estimates of $1.59 million. Aclaris Therapeutics had a negative net margin of 900.01% and a negative return on equity of 39.73%. As a group, equities analysts predict that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. CRA Financial Services LLC bought a new stake in shares of Aclaris Therapeutics during the second quarter worth approximately $25,000. ProShare Advisors LLC bought a new stake in shares of Aclaris Therapeutics during the 2nd quarter valued at $26,000. AXQ Capital LP acquired a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at $27,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Aclaris Therapeutics in the 2nd quarter worth $28,000. Finally, XTX Topco Ltd acquired a new stake in shares of Aclaris Therapeutics during the second quarter worth $34,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.